Natera, Inc. (NASDAQ:NTRA) CFO Sells $63,132.75 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 705 shares of the company’s stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $89.55, for a total transaction of $63,132.75. Following the completion of the transaction, the chief financial officer now directly owns 71,397 shares in the company, valued at approximately $6,393,601.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Stock Performance

Shares of NTRA stock traded up $0.38 during trading hours on Friday, hitting $91.66. The stock had a trading volume of 568,943 shares, compared to its average volume of 1,445,065. The firm has a market capitalization of $11.07 billion, a PE ratio of -24.18 and a beta of 1.37. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82. The stock’s 50 day moving average is $87.72 and its 200 day moving average is $67.16. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, research analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. CWM LLC lifted its holdings in shares of Natera by 224.4% during the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after purchasing an additional 911 shares during the period. Ellsworth Advisors LLC acquired a new stake in shares of Natera during the third quarter worth $364,000. Xponance Inc. lifted its holdings in shares of Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after purchasing an additional 261 shares during the period. Brown Advisory Inc. lifted its holdings in shares of Natera by 9.2% during the third quarter. Brown Advisory Inc. now owns 4,738 shares of the medical research company’s stock worth $210,000 after purchasing an additional 400 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Natera by 19.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,616 shares of the medical research company’s stock worth $912,000 after purchasing an additional 3,384 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Canaccord Genuity Group upped their target price on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Stephens restated an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. The Goldman Sachs Group upped their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a report on Friday, April 5th. Finally, StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.